PA8847901A1 - Combinación farmacéutica sinérgica que comprende un antagonista del receptor de estrógeno y una progestina - Google Patents
Combinación farmacéutica sinérgica que comprende un antagonista del receptor de estrógeno y una progestinaInfo
- Publication number
- PA8847901A1 PA8847901A1 PA20098847901A PA8847901A PA8847901A1 PA 8847901 A1 PA8847901 A1 PA 8847901A1 PA 20098847901 A PA20098847901 A PA 20098847901A PA 8847901 A PA8847901 A PA 8847901A PA 8847901 A1 PA8847901 A1 PA 8847901A1
- Authority
- PA
- Panama
- Prior art keywords
- progestine
- antigonist
- pharmaceutical combination
- receiver
- estrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008057230A DE102008057230A1 (de) | 2008-11-11 | 2008-11-11 | Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8847901A1 true PA8847901A1 (es) | 2010-06-28 |
Family
ID=41606625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20098847901A PA8847901A1 (es) | 2008-11-11 | 2009-11-09 | Combinación farmacéutica sinérgica que comprende un antagonista del receptor de estrógeno y una progestina |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR074297A1 (zh) |
| DE (1) | DE102008057230A1 (zh) |
| PA (1) | PA8847901A1 (zh) |
| TW (1) | TW201022251A (zh) |
| UY (1) | UY32235A (zh) |
| WO (1) | WO2010054758A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120238533A1 (en) * | 2009-09-11 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | (Heteroarylmethyl) Thiohydantoins as anticancer drugs |
| US20130231292A1 (en) * | 2012-03-02 | 2013-09-05 | Wei Zhou | Synergistic anti-proliferation activity of TAS-108 with mTOR inhibitors against cancer cells |
| US10112962B2 (en) * | 2014-07-02 | 2018-10-30 | Xavier University | Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group |
| CN104370796B (zh) * | 2014-11-21 | 2016-09-14 | 扬子江药业集团有限公司 | 一种醋酸巴多昔芬多晶型b的制备方法 |
| KR20180059427A (ko) * | 2015-07-14 | 2018-06-04 | 노벨파마 컴퍼니 리미티드 | 에스트로겐 수용체 α 저해 작용을 갖는 에스트로겐 수용체 β 부분 아고니스트 및 이를 사용한 부인과 질환 치료제 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| ID24568A (id) * | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
| US6265393B1 (en) | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
| WO2001009115A2 (en) * | 1999-07-29 | 2001-02-08 | Eli Lilly And Company | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE |
| DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE10159217A1 (de) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
| WO2003063859A1 (en) * | 2002-01-14 | 2003-08-07 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
| TW200307553A (en) * | 2002-05-24 | 2003-12-16 | Akzo Nobel Nv | Treatment of post-menopausal complaints in breast cancer patients |
| NZ537138A (en) | 2002-07-22 | 2007-11-30 | Lilly Co Eli | Selective estrogen receptor modulators containing a phenylsulfonyl group |
| US20080021003A1 (en) * | 2006-06-13 | 2008-01-24 | Vladimir Hanes | Extended step-down estrogen regimen |
-
2008
- 2008-11-11 DE DE102008057230A patent/DE102008057230A1/de not_active Withdrawn
-
2009
- 2009-10-31 WO PCT/EP2009/007801 patent/WO2010054758A1/en active Application Filing
- 2009-11-06 AR ARP090104296A patent/AR074297A1/es unknown
- 2009-11-09 PA PA20098847901A patent/PA8847901A1/es unknown
- 2009-11-10 UY UY0001032235A patent/UY32235A/es not_active Application Discontinuation
- 2009-11-11 TW TW098138262A patent/TW201022251A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY32235A (es) | 2010-06-30 |
| AR074297A1 (es) | 2011-01-05 |
| TW201022251A (en) | 2010-06-16 |
| DE102008057230A1 (de) | 2010-05-12 |
| WO2010054758A1 (en) | 2010-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY32819A (es) | Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2 | |
| CR20110455A (es) | Derivados de indol como antagonistas del receptor crth2 | |
| UY35177A (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
| GT201500233A (es) | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno | |
| CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
| GT201600056A (es) | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih | |
| GT201200147A (es) | Antagonistas de espiro-oxindol de mdm2 | |
| GT201300122A (es) | Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano | |
| CO6640327A2 (es) | Compuestos de pirazol como inhibidores del receptor sigma | |
| CR20150490A (es) | Derivados de piridina como inhibidores de la quinasa reorganizada durante la transfección (ret) | |
| ECSP15007420A (es) | Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno | |
| UY30829A1 (es) | Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
| CO6680708A2 (es) | Compuesto modulares de estrógenos y composiciones que comprenden los mismos | |
| GT201400187A (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
| CL2011003229A1 (es) | Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer. | |
| DOP2013000043A (es) | Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos | |
| HN2012000137A (es) | Derivados de 17 - hidroxi - 17 - pentafluoroetil - estra - 4, 9(10) - dien - 11 - arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades | |
| PA8847901A1 (es) | Combinación farmacéutica sinérgica que comprende un antagonista del receptor de estrógeno y una progestina | |
| CO6420342A2 (es) | Derivados de pirazol usados como antagonistas del receptor ccr4 | |
| CU20120175A7 (es) | Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| GT201300241A (es) | Composicion farmaceutica antihipertensiva | |
| CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 |